H.C. Wainwright lowered the firm’s price target on iTeos Therapeutics (ITOS) to $21 from $46 and keeps a Buy rating on the shares. The firm removed expected revenue from inupadenant in lung cancer following the interim data.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter